The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Future of Personalized Medicine in Oncology: A Systems Biology Approach
Open accessAbstract
The development of cost-effective technologies able to comprehensively assess DNA, RNA, protein, and metabolites in patient tumors has fueled efforts to tailor medical care. Indeed validated molecular tests assessing tumor tissue or patient germline DNA already drive therapeutic decision making. However, many theoretical and regulatory challenges must still be overcome before fully realizing the promise of personalized molecular medicine. The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient outcomes. Systems biology integrates engineering, physics, and mathematical approaches with biologic and medical insights in an iterative process to visualize the interconnected events within a cell that determine how inputs from the environment and the network rewiring that occurs due to the genomic aberrations acquired by patient tumors determines cellular behavior and patient outcomes. A cross-disciplinary systems biology effort will be necessary to convert the information contained in multidimensional data sets into useful biomarkers that can classify patient tumors by prognosis and response to therapeutic modalities and to identify the drivers of tumor behavior that are optimal targets for therapy. An understanding of the effects of targeted therapeutics on signaling networks and homeostatic regulatory loops will be necessary to prevent inadvertent effects as well as to develop rational combinatorial therapies. Systems biology approaches identifying molecular drivers and biomarkers will lead to the implementation of smaller, shorter, cheaper, and individualized clinical trials that will increase the success rate and hasten the implementation of effective therapies into the clinical armamentarium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Self-citationOncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Hennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874
Self-citationMolecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Engineering tumors with 3D scaffolds
Fischbach, C., Chen, R., Matsumoto, T., Schmelzle, T., Brugge, J. S., Polverini, P. J., & Mooney, D. J. (2007) · Nature Methods · doi:10.1038/nmeth1085 · Cited by 823
Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 597
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1939 · Cited by 586
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K. H., Fishman, D., et al. (2004) · Nature Medicine · doi:10.1038/nm1125 · Cited by 509
Self-citationBergamaschi, A., Kim, Y. H., Wang, P., Sørlie, T., Hernandez‐Boussard, T., Lonning, P. E., Tibshirani, R., Børresen‐Dale, A., & Pollack, J. R. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20366 · Cited by 506
Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2331323100 · Cited by 474
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J. J., Ladd-Acosta, C., Mesirov, J., Golub, T. R., & Jacks, T. (2005) · Nature Genetics · doi:10.1038/ng1490 · Cited by 414
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
Self-citationBautista, S., Valles, H., Walker, R. L., Anzick, S. L., Zeillinger, R., Meltzer, P. S., & Theillet, C. G. (1998) · PubMed · Cited by 231
Wulfkuhle, J. D., Aquino, J. A., Calvert, V. S., Fishman, D. A., Coukos, G., Liotta, L. A., & Petricoin, E. F. (2003) · PROTEOMICS · doi:10.1002/pmic.200300591 · Cited by 221
Wang, T.-L., Maierhofer, C., Speicher, M. R., Lengauer, C., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202610899 · Cited by 219
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8168 · Cited by 216
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Tham, Y.-L., Kalidas, M., Elledge, R., Mohsin, S., Osborne, C. K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.156 · Cited by 197
Signal pathway profiling of prostate cancer using reverse phase protein arrays
Grubb, R. L., Calvert, V. S., Wulkuhle, J. D., Paweletz, C. P., Linehan, W. M., Phillips, J. L., Chuaqui, R., Valasco, A., Gillespie, J., Emmert‐Buck, M., et al. (2003) · PROTEOMICS · doi:10.1002/pmic.200300598 · Cited by 194
Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0459 · Cited by 178
Self-citationBostner, J., Ahnström Waltersson, M., Fornander, T., Skoog, L., Nordenskjöld, B., & Stål, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210506 · Cited by 172
The Use of MassARRAY Technology for High Throughput Genotyping
Jurinke, C., van den Boom, D., Cantor, C. R., & Köster, H. (2002) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/3-540-45713-5_4 · Cited by 168
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Shih, I., Sheu, J. J., Santillan, A., Nakayama, K., Yen, M. J., Bristow, R. E., VANG, R. S., Parmigiani, G., Kurman, R. J., Trope, C. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504195102 · Cited by 146
Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays
Charboneau, L., Tory, H., Scott, H., Chen, T., Winters, M., Petricoin, E. F., Liotta, L. A., & Paweletz, C. P. (2002) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/1.3.305 · Cited by 128
Xi, L., Feber, A., Gupta, V., Wu, M., Bergemann, A. D., Landreneau, R. J., Litle, V. R., Pennathur, A., Luketich, J. D., & Godfrey, T. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn697 · Cited by 115
DNA methylation and cancer diagnosis: new methods and applications
Dehan, P., Kustermans, G., Guénin, S., Horion, J., Boniver, J., & Delvenne, P. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.53 · Cited by 102
Zha, H., Raffeld, M. A., Charboneau, L., Pittaluga, S., Kwak, L. W., Petricoin, E. F., Liotta, L. A., & Jaffe, E. S. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700051 · Cited by 88
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Y., & Calvert, H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1414.020 · Cited by 71
Tumor dormancy and oncogene addiction
Felsher, D. W. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.01037.x · Cited by 35
A Systems Approach to Analysis of Molecular Complexity in Breast Cancer
Hennessy, B. T., Gonzalez-Angulo, A. M., Carey, M. S., & Mills, G. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2620 · Cited by 20
Self-citationTargeting cancer-specific synthetic lethality in double-strand DNA break repair
Moeller, B. J., Pasqualini, R., & Arap, W. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8743 · Cited by 19
Cited by
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
The impact of next-generation sequencing on genomics
Zhang, J., Chiodini, R., Badr, A., & Zhang, G. (2011) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2011.02.003 · Cited by 577
“There is no doubt that the progress of genomics will eventually lead to the birth of genetic medicine which will propel significant advances and improvements in human health (Gonzalez-Angulo et al., 2010).”
BackgroundVan Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Ultrasensitive detection of nucleic acids using deformed graphene channel field effect biosensors
Hwang, M. T., Heiranian, M., Kim, Y., You, S., Leem, J., Taqieddin, A., Faramarzi, V., Jing, Y., Park, I., van der Zande, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15330-9 · Cited by 433
Personalized Medicine: Progress and Promise
Chan, I. S., & Ginsburg, G. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101446 · Cited by 399
Metadata
- Authors
- Gonzalez-Angulo, A. M., Hennessy, B. T. J., & Mills, G. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-06-01
- Volume
- 28
- Issue
- 16
- Pages
- 2777-2783
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2029532166
- Cited by
- 261
- References
- 45
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.